Full Text:  <924>

CLC number: R54

On-line Access: 

Received: 2004-12-17

Revision Accepted: 2005-04-03

Crosschecked: 0000-00-00

Cited: 4

Clicked: 2694

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2005 Vol.6 No.9 P.877~884


Brain natriuretic peptide and optimal management of heart failure

Author(s):  LI Nan, WANG Jian-an

Affiliation(s):  Division of Clinical Pharmacology and Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China

Corresponding email(s):   nli_zum@yahoo.com.cn, wang_jian_an@tom.com

Key Words:  Brain natriuretic peptide (BNP), Heart failure, Drug therapy

LI Nan, WANG Jian-an. Brain natriuretic peptide and optimal management of heart failure[J]. Journal of Zhejiang University Science B, 2005, 6(6): 877~884.

@article{title="Brain natriuretic peptide and optimal management of heart failure",
author="LI Nan, WANG Jian-an",
journal="Journal of Zhejiang University Science B",
publisher="Zhejiang University Press & Springer",

%0 Journal Article
%T Brain natriuretic peptide and optimal management of heart failure
%A LI Nan
%A WANG Jian-an
%J Journal of Zhejiang University SCIENCE B
%V 6
%N 9
%P 877~884
%@ 1673-1581
%D 2005
%I Zhejiang University Press & Springer

T1 - Brain natriuretic peptide and optimal management of heart failure
A1 - LI Nan
A1 - WANG Jian-an
J0 - Journal of Zhejiang University Science B
VL - 6
IS - 9
SP - 877
EP - 884
%@ 1673-1581
Y1 - 2005
PB - Zhejiang University Press & Springer
ER -

Aside from the important role of brain natriuretic peptide (BNP) in diagnosis, and differential diagnosis of heart failure, this biological peptide has proved to be an independent surrogate marker of rehospitalization and death of the fatal disease. Several randomized clinical trials demonstrated that drugs such as beta blocker, angiotensin converting enzyme inhibitor, spironolactone and amiodarone have beneficial effects in decreasing circulating BNP level during the management of chronic heart failure. The optimization of clinical decision-making appeals for a representative surrogate marker for heart failure prognosis. The serial point-of-care assessments of BNP concentration provide a therapeutic goal of clinical multi-therapy and an objective guidance for optimal treatment of heart failure. Nevertheless new questions and problems in this area remain to be clarified. On the basis of current research advances, this article gives an overview of BNP peptide and its property and role in the management of heart failure.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article